{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T22:55:22Z","timestamp":1790808922268,"version":"4.1.0"},"reference-count":32,"publisher":"American Psychiatric Association Publishing","issue":"10","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["AJP"],"published-print":{"date-parts":[[2002,10,1]]},"DOI":"10.1176\/appi.ajp.159.10.1702","type":"journal-article","created":{"date-parts":[[2002,10,2]],"date-time":"2002-10-02T00:03:55Z","timestamp":1033517035000},"page":"1702-1710","source":"Crossref","is-referenced-by-count":72,"title":["Inhibition of Norepinephrine Uptake in Patients With Major Depression Treated With Paroxetine"],"prefix":"10.1176","volume":"159","author":[{"given":"Michelle L.","family":"Gilmor","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael J.","family":"Owens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles B.","family":"Nemeroff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"230","reference":[{"key":"atypb1","doi-asserted-by":"crossref","unstructured":"Nelson JC: A review of the efficacy of serotonergic and noradrenergic reuptake inhibitors for treatment of major depression. Biol Psychiatry 1999; 46:1301-1308","DOI":"10.1016\/S0006-3223(99)00173-0"},{"key":"R15910CFAHCGJA","doi-asserted-by":"crossref","unstructured":"Steffens DC, Krishnan KRR, Helms MJ: Are SSRIs better than TCAs? comparison of SSRIs and TCAs: a meta-analysis. Depress Anxiety 1997; 6:10-18","DOI":"10.1002\/(SICI)1520-6394(1997)6:1<10::AID-DA2>3.0.CO;2-9"},{"key":"R15910CFAJGGJH","doi-asserted-by":"crossref","unstructured":"Thase ME, Entsuah AR, Rudolph RL: Remission rates during treatment with venlafaxine or selective serotonin reuptake inhibitors. Br J Psychiatry 2001; 178:234-241","DOI":"10.1192\/bjp.178.3.234"},{"key":"R15910CFAFCDGE","doi-asserted-by":"crossref","unstructured":"Nelson JC, Mazure CM, Bowers Jr. MB, Jatlow PI: A preliminary, open study of the combination of fluoxetine and desipramine for rapid treatment of major depression. Arch Gen Psychiatry 1991; 48:303-307","DOI":"10.1001\/archpsyc.1991.01810280019002"},{"key":"R15910CFAFEFEH","doi-asserted-by":"crossref","unstructured":"Seth R, Jennings AL, Bindman J, Phillips J, Bergmann K: Combination treatment with noradrenalin and serotonin reuptake inhibitors in resistant depression. Br J Psychiatry 1992; 161:562-565","DOI":"10.1192\/bjp.161.4.562"},{"key":"R15910CFAEJAEI","doi-asserted-by":"crossref","unstructured":"Muth EA, Haskins JT, Moyer JA, Husbands GE, Nielsen ST, Sigg EB: Antidepressant biochemical profile of the novel bicyclic compound Wy-45,030, an ethyl cyclohexanol derivative. Biochem Pharmacol 1986; 35:4493-4497","DOI":"10.1016\/0006-2952(86)90769-0"},{"key":"R15910CFAHACJH","unstructured":"Owens MJ, Morgan WN, Plott SJ, Nemeroff CB: Neurotransmitter receptor and transporter binding profile of antidepressants and their metabolites. J Pharmacol Exp Ther 1997; 283:1305-1322"},{"key":"atypb2","doi-asserted-by":"crossref","unstructured":"Tatsumi M, Groshan K, Blakely RD, Richelson E: Pharmacological profile of antidepressants and related compounds at human monoamine transporters. Eur J Pharmacol 1997; 340:249-258","DOI":"10.1016\/S0014-2999(97)01393-9"},{"key":"atypb3","doi-asserted-by":"crossref","unstructured":"Beique J-C, Lavoie N, de Montigny C, Debonnel G: Affinities of venlafaxine and various reuptake inhibitors for the serotonin and norepinephrine transporters. Eur J Pharmacol 1998; 349:129-132","DOI":"10.1016\/S0014-2999(98)00241-6"},{"key":"R15910CFAHHBDE","doi-asserted-by":"crossref","unstructured":"Owens MJ, Knight DL, Nemeroff CB: Second generation SSRIs: human monoamine transporter binding profile of S-citalopram and R-fluoxetine. Biol Psychiatry 2001; 50:345-350","DOI":"10.1016\/S0006-3223(01)01145-3"},{"key":"R15910CFAJJIJE","doi-asserted-by":"crossref","unstructured":"Owens MJ, Knight DL, Nemeroff CB: Paroxetine binding to the rat norepinephrine transporter in vivo. Biol Psychiatry 2000; 47:842-845","DOI":"10.1016\/S0006-3223(99)00314-5"},{"key":"R15910CFAEBBGE","doi-asserted-by":"crossref","unstructured":"Montgomery SA, \u00c5sberg M: A new depression scale designed to be sensitive to change. Br J Psychiatry 1979; 134:382-389","DOI":"10.1192\/bjp.134.4.382"},{"key":"R15910CFAIEBBI","doi-asserted-by":"crossref","unstructured":"Gunasekara NS, Noble S, Benfield P: Paroxetine: an update of its pharmacology and therapeutic use in depression and a review of its use in other disorders. Drugs 1998; 55:85-120","DOI":"10.2165\/00003495-199855010-00007"},{"key":"R15910CFADGBIJ","doi-asserted-by":"crossref","unstructured":"Kaye CM, Haddock RE, Langley PF, Mellows G, Tasker TCG, Zussman BD, Greb WH: A review of the metabolism and pharmacokinetics of paroxetine in man. Acta Psychiatr Scand Suppl 1989; 350:60-75","DOI":"10.1111\/j.1600-0447.1989.tb07176.x"},{"key":"R15910CFADBDIJ","doi-asserted-by":"crossref","unstructured":"Lundmark J, Bengtsson F, Nordin C, Reis M, Walinder J: Therapeutic drug monitoring of selective serotonin reuptake inhibitors influences clinical dosing strategies and reduces drug costs in depressed elderly patients. Acta Psychiatr Scand 2000; 101:354-359","DOI":"10.1034\/j.1600-0447.2000.101005354.x"},{"key":"atypb5","doi-asserted-by":"crossref","unstructured":"Tasker TCG, Kaye CM, Zussman BD, Link CGG: Paroxetine plasma levels: lack of correlation with efficacy or adverse events. Acta Psychiatr Scand Suppl 1989; 350:152-155","DOI":"10.1111\/j.1600-0447.1989.tb07201.x"},{"key":"R15910CFAHBAGI","doi-asserted-by":"crossref","unstructured":"Danish University Antidepressant Group: Paroxetine: a selective serotonin reuptake inhibitor showing better tolerance, but weaker antidepressant effect than clomipramine in a controlled multicenter study. J Affect Disord 1990; 18:289-299","DOI":"10.1016\/0165-0327(90)90081-I"},{"key":"R15910CFAFHBCJ","doi-asserted-by":"crossref","unstructured":"Sindrup SH, Brosen K, Gram LF: Pharmacokinetics of the selective serotonin reuptake inhibitor paroxetine: nonlinearity and relation to the sparteine oxidation polymorphism. Clin Pharmacol Ther 1992; 51:288-295","DOI":"10.1038\/clpt.1992.24"},{"key":"R15910CFABECGE","doi-asserted-by":"crossref","unstructured":"Muscettola G, Goodwin FK, Potter WZ, Claeys MM, Markey SP: Imipramine and desipramine in plasma and spinal fluid: relationship to clinical response and serotonin metabolism. Arch Gen Psychiatry 1978; 35:621-625","DOI":"10.1001\/archpsyc.1978.01770290103009"},{"key":"R15910CFAFGHEJ","unstructured":"Forsman A, Ohman R: Studies on serum protein binding of haloperidol. Curr Ther Res Clin Exp 1977; 21:245-255"},{"key":"R15910CFAFJFBH","doi-asserted-by":"crossref","unstructured":"Linkowski P, Hubain P, von Frenckell R, Mendlewicz J: Haloperidol plasma levels and clinical response in paranoid schizophrenics. Eur Arch Psychiatry Neurol Sci 1984; 234:231-236","DOI":"10.1007\/BF00381354"},{"key":"R15910CFABHCID","doi-asserted-by":"crossref","unstructured":"Hanin I, Koslow SH, Kocsis JH, Bowden CL, Brunswick D, Frazer A, Carl J, Robins E: Cerebrospinal fluid levels of amitriptyline, nortriptyline, imipramine and desmethylimipramine. J Affect Disord 1985; 9:69-78","DOI":"10.1016\/0165-0327(85)90012-6"},{"key":"R15910CFADGJIE","doi-asserted-by":"crossref","unstructured":"Potter WZ, Scheinin M, Golden RN, Rudorfer MV, Wowdry RW, Calil HM, Ross RJ, Linnoila M: Selective antidepressants and cerebrospinal fluid: lack of specificity on norepinephrine and serotonin metabolites. Arch Gen Psychiatry 1985; 42:1171-1177","DOI":"10.1001\/archpsyc.1985.01790350045009"},{"key":"R15910CFAHJGAC","doi-asserted-by":"crossref","unstructured":"Martensson B, Nyberg S, Toresson G, Brodin E, Bertilsson L: Fluoxetine treatment of depression. Acta Psychiatr Scand 1989; 79:586-596","DOI":"10.1111\/j.1600-0447.1989.tb10307.x"},{"key":"R15910CFACEIDJ","doi-asserted-by":"crossref","unstructured":"Lundmark J, Walinder J, Alling C, Manniche PM, Dalgaard L: The effect of paroxetine on cerebrospinal fluid concentrations of neurotransmitter metabolites in depressed patients. Eur Neuropsychopharmacol 1994; 4:1-6","DOI":"10.1016\/0924-977X(94)90308-5"},{"key":"R15910CFABFCCC","doi-asserted-by":"crossref","unstructured":"Andrews JM, Ninan PT, Nemeroff CB: Venlafaxine: a novel antidepressant that has a dual mechanism of action. Depression 1996; 4:48-56","DOI":"10.1002\/(SICI)1522-7162(1996)4:2<48::AID-DEPR2>3.0.CO;2-B"},{"key":"R15910CFAIIJDF","doi-asserted-by":"crossref","unstructured":"Harvey AT, Rudolph RL, Preskorn SH: Evidence of the dual mechanisms of action of venlafaxine. Arch Gen Psychiatry 2000; 57:503-509","DOI":"10.1001\/archpsyc.57.5.503"},{"key":"R15910CFAFIJHC","doi-asserted-by":"crossref","unstructured":"Poirier M-F, Boyer P: Venlafaxine and paroxetine in treatment-resistant depression. Br J Psychiatry 1999; 175:12-16","DOI":"10.1192\/bjp.175.1.12"},{"key":"R15910CFAIACHB","doi-asserted-by":"crossref","unstructured":"Ballus C, Quiros G, De Flores T, de la Torre J, Palao D, Rojo L, Gutierrez M, Casais L, Riesgo Y: The efficacy and tolerability of venlafaxine and paroxetine in outpatients with depressive disorder or dysthymia. Int Clin Psychopharmacol 2000; 15:43-48","DOI":"10.1097\/00004850-200015010-00007"},{"key":"R15910CFAHGICA","doi-asserted-by":"crossref","unstructured":"Franchini L, Gasperini M, Perez J, Smeraldi E, Zanardi R: Dose-response efficacy of paroxetine in preventing depressive recurrences: a randomized, double-blind study. J Clin Psychiatry 1998; 59:229-232","DOI":"10.4088\/JCP.v59n0504"},{"key":"R15910CFAEFGGF","doi-asserted-by":"crossref","unstructured":"Tyrer P, Marsden CA, Casey P, Seivewright N: Clinical efficacy of paroxetine in resistant depression. J Psychopharmacol 1987; 1:251-257","DOI":"10.1177\/026988118700100406"},{"key":"R15910CFAFJEEF","doi-asserted-by":"crossref","unstructured":"Javors MA, Houston JP, Tekell JL, Brannan SK, Frazer A: Reduction of platelet serotonin content in depressed patients treated with either paroxetine or desipramine. Int J Neuropsychopharmacol 2000; 3:229-235","DOI":"10.1017\/S146114570000198X"}],"container-title":["American Journal of Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/psychiatryonline.org\/doi\/10.1176\/appi.ajp.159.10.1702","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,28]],"date-time":"2024-07-28T14:12:34Z","timestamp":1722175954000},"score":1,"resource":{"primary":{"URL":"https:\/\/psychiatryonline.org\/doi\/10.1176\/appi.ajp.159.10.1702"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2002,10,1]]},"references-count":32,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2002,10,1]]}},"alternative-id":["10.1176\/appi.ajp.159.10.1702"],"URL":"https:\/\/doi.org\/10.1176\/appi.ajp.159.10.1702","relation":{},"ISSN":["0002-953X","1535-7228"],"issn-type":[{"value":"0002-953X","type":"print"},{"value":"1535-7228","type":"electronic"}],"subject":[],"published":{"date-parts":[[2002,10,1]]}}}